Wedbush Forecasts Reduced Earnings for Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities research analysts at Wedbush decreased their Q2 2025 EPS estimates for Y-mAbs Therapeutics in a research note issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.29) per share for the quarter, down from their previous forecast of ($0.25). Wedbush has a “Outperform” rating and a $23.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.08) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.63) EPS and FY2028 earnings at ($1.78) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $20.90 million for the quarter, compared to analysts’ expectations of $19.97 million.

Other equities analysts also recently issued research reports about the company. Oppenheimer cut their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. HC Wainwright dropped their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Truist Financial dropped their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Bank of America downgraded Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.70.

Y-mAbs Therapeutics Stock Performance

YMAB opened at $4.10 on Thursday. The stock’s 50 day moving average price is $4.47 and its 200-day moving average price is $7.11. The stock has a market cap of $185.64 million, a price-to-earnings ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics has a one year low of $3.55 and a one year high of $16.11.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors have recently made changes to their positions in the company. Brooklyn Investment Group increased its holdings in shares of Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock valued at $26,000 after purchasing an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics in the 4th quarter valued at $46,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Y-mAbs Therapeutics in the 1st quarter valued at $49,000. Corton Capital Inc. acquired a new stake in Y-mAbs Therapeutics in the 1st quarter valued at $55,000. Finally, EntryPoint Capital LLC acquired a new stake in Y-mAbs Therapeutics in the 1st quarter valued at $56,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.